title: Racially restricted contribution of immunoglobulin Fcγ and Fcγ receptor genotypes to humoral immunity to human epidermal growth factor receptor 2 in breast cancer.
abstract: Tumour-associated antigen human epidermal growth factor receptor 2 (HER2) is over-expressed in 25-30% of breast cancer patients and is associated with poor prognosis. Naturally occurring anti-HER2 antibody responses have been described in patients with HER2 over-expressing tumours. There is significant interindividual variability in antibody responsiveness, but the host genetic factors responsible for this variability are poorly understood. The aim of the present investigation was to determine whether immunoglobulin genetic markers [GM (genetic determinants of γ chains)] and Fcγ receptor (FcγR) alleles contribute to the magnitude of natural antibody responsiveness to HER2 in patients with breast cancer. A total of 855 breast cancer patients from Japan and Brazil were genotyped for several GM and FcγR alleles. They were also characterized for immunoglobulin (Ig)G antibodies to HER2. In white subjects (n = 263), GM 23-carriers had higher levels of anti-HER2 antibodies than non-carriers of this allele (p = 0·004). At the GM 5/21 locus, the homozygotes for the GM 5 allele had higher levels of anti-HER2 antibodies than the other two genotypes (P = 0·0067). In black subjects (n = 42), FcγRIIa-histidine/histidine homozygotes and FcγRIIIa-phenylalanine/valine heterozygotes were associated with high antibody responses (P = 0·0071 and 0·0275, respectively). FcγR genotypes in white subjects and GM genotypes in black subjects were not associated with anti-HER2 antibody responses. No significant associations were found in other study groups. These racially restricted contributions of GM and FcγR genotypes to humoral immunity to HER2 have potential implications for immunotherapy of breast cancer.
authors: Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425-2230, USA. pandeyj@musc.edu
authors: J P
authors: JP
authors: Pandey
authors: A M
authors: AM
authors: Namboodiri
authors: E
authors: E
authors: Kistner-Griffin
authors: M
authors: M
authors: Iwasaki
authors: Y
authors: Y
authors: Kasuga
authors: G S
authors: GS
authors: Hamada
authors: S
authors: S
authors: Tsugane
mesh_terms: D000483:Alleles; D044466:Asian People / Q000235:genetics; D044383:Black People / Q000235:genetics; D001938:Brazil; D001943:Breast Neoplasms / Q000235:genetics* / Q000276:immunology* / Q000628:therapy; D005260:Female; D005838:Genotype; D006801:Humans; D056724:Immunity, Humoral / Q000235:genetics*; D007129:Immunoglobulin Gm Allotypes / Q000235:genetics*; D007167:Immunotherapy; D007564:Japan; D044469:Racial Groups / Q000235:genetics*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology*; D017452:Receptors, IgG / Q000235:genetics*; D044465:White People / Q000235:genetics
chemical_list: D007129:Immunoglobulin Gm Allotypes; D018719:Erb-b2 Receptor Tyrosine Kinases; D017452:Receptors, IgG; C508053:ERBB2 protein, human
references: Int Immunol. 1990;2(4):317-22
references: 2278990
references: J Clin Oncol. 2009 Oct 1;27(28):4685-92
references: 19720923
references: J Clin Oncol. 2008 Apr 10;26(11):1789-96
references: 18347005
references: Hum Immunol. 2010 Nov;71(11):1124-7
references: 20736037
references: Clin Exp Immunol. 2011 Dec;166(3):361-5
references: 22059994
references: Am J Phys Anthropol. 2004 Oct;125(2):175-92
references: 15365983
references: Exp Clin Immunogenet. 1995;12(3):191-7
references: 8534505
references: Expert Rev Vaccines. 2011 Feb;10(2):201-10
references: 21332269
references: Breast Cancer Res Treat. 2011 Apr;126(2):497-505
references: 20697800
references: Immunogenetics. 1995;42(5):414-7
references: 7590976
references: Cancer Immunol Immunother. 2003 Dec;52(12):715-38
references: 12920480
references: Breast Cancer Res Treat. 2000 Aug;62(3):245-52
references: 11072789
references: Immunogenetics. 1994;39(3):187-93
references: 8276465
references: J Immunol. 2011 Feb 1;186(3):1299; author reply 1299
references: 21248266
references: Genes Immun. 2004 Jan;5(1):68-71
references: 14735152
references: J Surg Oncol. 2012 Apr 1;105(5):452-8
references: 22441896